Checkpoint Therapeutics Announces Data Presentation at the European Society for Medical Oncology (ESMO) Congress 2019
September 16, 2019 07:30 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition,...
Checkpoint Therapeutics to Present at September 2019 Investor Conferences
September 04, 2019 08:30 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition,...
Checkpoint Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights
August 08, 2019 16:30 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition,...
Checkpoint Therapeutics Added to Russell 2000® Index
July 01, 2019 08:30 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, July 01, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition,...
Checkpoint Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights
May 09, 2019 17:00 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, May 09, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition,...
Checkpoint Therapeutics Announces Positive Interim Clinical Results of Anti-PD-L1 Antibody Cosibelimab
May 01, 2019 07:30 ET
|
Checkpoint Therapeutics, Inc
>40% objective response rates observed in first-line non-small cell lung cancer and cutaneous squamous cell carcinoma Well-tolerated safety profile Enrollment ongoing in expansion cohorts...
Checkpoint Therapeutics to Present at the 2019 H.C. Wainwright Global Life Sciences Conference
April 03, 2019 08:30 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, April 03, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition,...
Checkpoint Therapeutics Reports Full-Year 2018 Financial Results and Recent Corporate Highlights
March 15, 2019 07:30 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, March 15, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition,...
Checkpoint Therapeutics Announces Issuance of Two New Patents for EGFR Inhibitor CK-101
March 13, 2019 08:30 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, March 13, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition,...
Checkpoint Therapeutics Initiates Registrational Development Programs for Anti-PD-L1 Antibody CK-301
January 07, 2019 08:30 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition,...